We are live on ! Find out more
ZBIO

ProShares UltraPro Short NASDAQ Biotechnology
ZBIO

Delisted

ZBIO was delisted on the 27th of March, 2020.

Back to rankings

5 hedge funds and large institutions have $441K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more funds holding

Funds holding: 5 → 5 (0)

26% less capital invested

Capital invested by funds: $596K → $441K (-$155K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$94.7K
2
TRCT
Tower Research Capital (TRC)
New York
+$81K
3
Morgan Stanley
Morgan Stanley
New York
+$22.4K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$24.8K
2
Citadel Advisors
Citadel Advisors
Florida
-$16.9K

ZBIO Hedge Fund Activity: Q4 2019 in Review

5 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q4 2019, worth a combined $441K — down 26% from $596K a quarter earlier.

Fund positioning in ZBIO was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $94.7K. The largest seller was UBS Group, cutting an estimated $24.8K.

  • 5 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $441K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q4 2019, down 26% quarter-over-quarter.
  • 0 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q4 2019 and 0 closed out.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q4 2019 was Susquehanna International Group, an estimated $94.7K added.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q4 2019 was UBS Group, an estimated $24.8K sold.

Based on aggregated 13F filings for Q4 2019.